NASDAQ: NURONeurometrix Inc Stock
$4.44-0.13 (-2.84%)
Updated Apr 23, 2024
NURO Price
$4.44
Fair Value Price
$19.81
Market Cap
$8.82M
52 Week Low
$2.70
52 Week High
$11.60
P/E
-0.71x
P/B
0.44x
P/S
0.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.90M
Earnings
-$6.53M
Gross Margin
66.9%
Operating Margin
-110.64%
Profit Margin
-110.6%
Debt to Equity
0.07
Operating Cash Flow
-$6M
Beta
1.02
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NURO Overview
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NURO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NURO ($4.44) is undervalued by 77.59% relative to our estimate of its Fair Value price of $19.81 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NURO ($4.44) is significantly undervalued by 77.59% relative to our estimate of its Fair Value price of $19.81 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NURO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NURO due diligence checks available for Premium users.
Be the first to know about important NURO news, forecast changes, insider trades & much more!
NURO News
Valuation
NURO fair value
Fair Value of NURO stock based on Discounted Cash Flow (DCF)
Price
$4.44
Fair Value
$19.81
Undervalued by
77.59%
NURO ($4.44) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NURO ($4.44) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NURO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NURO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.71x
Industry
29.66x
Market
41.92x
NURO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.44x
Industry
3.71x
NURO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NURO's financial health
Profit margin
Revenue
$1.3M
Net Income
-$1.6M
Profit Margin
-125.2%
NURO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NURO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.4M
Liabilities
$1.3M
Debt to equity
0.07
NURO's short-term assets ($20.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NURO's short-term assets ($20.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NURO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NURO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$98.0k
Financing
$1.6M
NURO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NURO vs Medical Device Stocks
Neurometrix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.